Table 4 Comparison of clinicopathological characteristics of 255 HER2-positive patients without trastuzumab
Factors | Group 1 | p-value | |
|---|---|---|---|
Low pre-NLR | High pre-NLR | ||
Age (year) | |||
≤ 40 | 14 (11.0) | 17 (13.3) | 0.581 |
> 40 | 113 (89.0) | 111 (86.7) | |
T stage | |||
T1 | 29 (22.8) | 22 (17.2) | |
T2 | 82 (64.6) | 90 (70.3) | 0.515 |
T3–4 | 16 (12.6) | 16 (12.5) | |
N stage | |||
pN0 | 68 (53.5) | 76 (59.4) | |
pN1 | 41 (32.3) | 35 (27.3) | 0.624 |
pN2–3 | 18 (14.2) | 17 (13.3) | |
Histological grade | |||
1~2 | 98 (77.2) | 100 (78.1) | 0.854 |
3 | 29 (22.8) | 28 (21.9) | |
HR | |||
Negative | 72 (56.7) | 73 (57.0) | 0.957 |
Positive | 55 (43.3) | 130 (43.0) | |
Ki67 (%) | |||
< 30 | 67 (52.8) | 57 (44.5) | 0.189 |
≥ 30 | 60 (47.2) | 71 (55.5) | |
NC | |||
No | 59 (46.5) | 58 (45.3) | 0.855 |
Yes | 68 (53.5) | 70 (54.7) | |
Total | 127 (100.0) | 128 (100.0) | |